Open Access

Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters

Lipids in Health and Disease201716:140

https://doi.org/10.1186/s12944-017-0536-0

Received: 7 June 2017

Accepted: 13 July 2017

Published: 21 July 2017

Abstract

Background

Lysophosphatidic acid (LPA) is a bioactive lipid with a wide biological activity. Previous studies have shown its potential usefulness as a diagnostic marker for ovarian cancer. The aim of the study was to investigate which factors may influence plasma LPA concentrations in healthy subjects and to propose reference values.

Methods

The study group consisted of 100 healthy subjects. From all of them the blood samples were taken at 7 a.m. (fasting state). From 40 volunteers additional blood samples were taken at 2 p.m., at 8 p.m. and at 2 a.m. next morning. Concentrations of LPA were measured in plasma samples using enzyme-linked immunosorbent assay.

Results

Analysis of samples from 100 healthy volunteers showed significant influence of sex and age on plasma LPA. The reference range for the plasma LPA concentration corrected for age and sex, determined at 2.5–97.5 percentile interval is 0.14–1.64 μM. LPA correlates positively with BMI, serum total cholesterol, triacylglycerols, uric acid and negatively with estimated glomerular filtration rate and serum albumin. Concentration of LPA at 2 a.m. was lower than at 2 p.m. There were not any significant differences between plasma LPA at 7 a.m. and any other time of the day.

Conclusions

Plasma LPA is associated with demographic, anthropometric and biochemical parameters. It seems that LPA concentrations have no specific circadian rhythm and the time of donation and fasting state have marginal effect on plasma LPA. These findings may be helpful in future incorporation of LPA as a diagnostic marker.

Keywords

Lysophosphatidic acid Lysophospholipids Reference values Antropometric parameters Demographic parameters Circadian rhythm Healthy subjects

Background

Lysophosphatidic acid (LPA) is a bioactive lysophospholipid present both intra- and extracellularly. Intracellular LPA is an intermediate metabolite in the synthesis of other phospholipids. Extracellular LPA acts through specific G protein coupled receptors (GPCR) belonging to the endothelial differentiation gene (LPA1–3) or purinergic (LPA4–6) receptors family, which are present on the surface of numerous cell types [1]. Activation of LPA receptors results in enhanced proliferation, migration and invasiveness, inhibition of apoptosis, morphological changes, inhibition of differentiation, contraction, increased endothelial permeability, platelet aggregation and cytokine secretion. The effect of LPA administration is dependent on the activated receptor, type of the cell and molecular species of LPA [2, 3].

Despite its simple structure, LPA is important element of proper development and functioning of variety tissues and organ systems. It was shown, that LPA participates in development of nervous [4, 5] and circulatory [6] system, functioning of male and female reproductive system [7], bone metabolism [8], hair follicles development [9], wound healing [10] and functioning of immune system [7]. On the other hand abnormalities in LPA signaling are involved in cancer progression [11] atherosclerosis [3], neuropathic pain [12], neuropsychiatric disorders [1], autoimmune diseases [1] and renal and pulmonary fibrosis [13, 14].

The main sources of LPA in blood are other lysophospholipids, especially lysophosphatidylcholine (LPC) and the reaction of hydrolysis of lysophospholipids to LPA is catalyzed by autotaxin (ATX) and its activity of lysophospholipase D [15]. LPA is present in multiple body fluids, such as blood [16, 17], saliva [18] and urine [19]. Serum concentrations of LPA are higher than in plasma, which is probably caused by secretion of LPA by activated platelets [20].

There are several studies indicating that plasma LPA is promising diagnostic marker for ovarian cancer (for meta-analysis see [21]). LPA concentrations in ovarian cancer patients are elevated already in the early stages of the disease [17]. Other conditions related to increased LPA plasma concentrations are acute coronary [22], chronic hepatitis C [23] and renal failure [24]. Due to the potential usefulness of LPA as a diagnostic marker the aim of the study was to investigate which factors may influence plasma LPA concentrations in healthy subjects and to propose reference values. This knowledge may be helpful for proper interpretation of elevated LPA plasma concentrations.

Methods

The study group consisted of 100 healthy volunteers from Szczecin in Poland. The intent of the study was to provide a baseline of LPA measurement as a diagnostic marker for ovarian (and possibly) other cancers, therefore in the study group “healthy” means cancer free, not necessarily free of any physical issues. The inclusion criterion was the age over 18 years old. The exclusion criteria were lack of the informed consent, pregnancy, diabetes and other metabolic diseases, acute and chronic inflammatory diseases and malignant neoplasms. The study had approval from the Local Bioethics Committee at the Pomeranian Medical University in Szczecin and written informed consent was obtained from all volunteers. Characteristics of the study group are presented in Tables 1 and 2.
Table 1

Baseline characteristics of the study group

Parameter

 

Total

Women

Men

p*

N

 

100

53

47

Smoking (yes/no)

 

21/79

13/40

8/39

Age [years]

Mean ± SD

39.6 ± 14.5

37.5 ± 14.8

41.9 ± 13.9

0.057

Median

34.0

30.0

37.0

Body mass [kg]

Mean ± SD

73.4 ± 14.9

65.2 ± 12.0

82.6 ± 12.3

<0.001

Median

72.0

61.0

80.0

BMI [kg/m2]

Mean ± SD

24.8 ± 4.0

24.0 ± 4.3

25.6 ± 3.4

0.009

Median

24.0

22.7

25.5

*Mann-Whitney test for difference between women and men

Table 2

A history of past/chronic diseases in the study group

Disease

Number

Arterial hypertension

6

Atherosclerosis

3

Varicose veins

7

A history of hypothyroidism

1

A history of bronchitis / pneumonia

10

A history of cholelithiasis

4

A history of gastric / duodenal ulcer

3

A history of urolithiasis

1

The blood samples were taken from all of the volunteers in the morning at about 7 a.m. (fasting state). Additional blood samples were collected at 2 p.m., 8 p.m., and 2 a.m. next morning from a subgroup of 40 volunteers (18 women and 22 men, mean age 33 ± 9 years, median 30 years). The blood samples were taken from a peripheral vein and placed in tubes containing ethylenediaminetetraacetic acid (K2EDTA) as anticoagulant and in tubes without anticoagulant and centrifuged (10 min, 1000 g, 20 °C) within half an hour from donation. In the case of an incomplete clotting in the sample without anticoagulant time to centrifugation was prolonged to one hour. Obtained plasma and serum samples were frozen and stored in −80 °C until used.

Basic biochemical parameters including total protein (TP), albumin, glucose, total cholesterol (TC), triacylglycerols (TAG), HDL-cholesterol (HDL-C) (precipitation method with phosphotungstic acid and magnesium chloride), and uric acid (UA) were measured in the serum samples using reagent kits from BioMaxima (Lublin, Poland). Absorbances of the samples were measured using a microplate reader EnVision 2104 Multilabel Reader (Perkin Elmer). LDL-cholesterol (LDL-C) concentrations were calculated from TC, HDL-C, and TAG using the Friedewald formula. The concentrations of serum creatinine were measured using a kit reagent from BioMaxima (Lublin, Poland). Kinetic measurements of absorbances were performed using the Specord 250 (Analytik Jena). Estimated glomerular filtration rate (eGFR) was calculated on the basis of age, gender and serum creatinine concentration using CKD-EPI formula [25]. Plasma lysophosphatidic acid concentrations were measured using competitive enzyme-linked immunosorbent assay (LPA Assay Kit II from Echelon Biosciences Inc., Salt Lake City, United States of America; Cat no. K-2800S). The absorbance was measured using microplate reader described above.

Statistical analysis was performed using Statistica 12 (StatSoft Inc.). The Shapiro-Wilk test was used to investigate the normality of distribution. Most of the variables were non-normally distributed, therefore the nonparametric tests were used to investigate the significance of differences between groups (Mann-Whitney U test for independent groups, Friedman ANOVA and Wilcoxon signed-rank test for comparisons of dependent measurements) and correlations between variables (Spearman’s rank correlation coefficient). General linear model (GLM) was used to analyze association of age and sex with LPA plasma concentration, which was transformed logarithmically to normalize its distribution. Differences were considered as statistically significant if p-values were less than 0.05.

Results

LPA fasting plasma concentrations in healthy volunteers ranged from 0.06 to 3.46 μM. In the women subgroup they were significantly higher than in men (Table 3).
Table 3

LPA fasting concentrations in plasma samples of 100 healthy volunteers (μM)

 

Number

Mean

SD

Minimum

Maximum

Lower quartile

Median

Upper quartile

p*

Total

100

0.89

0.60

0.06

3.46

0.49

0.74

1.12

 

Women

53

1.00

0.66

0.06

3.46

0.60

0.83

1.17

0.026

Men

47

0.77

0.50

0.15

2.04

0.39

0.63

0.98

*Mann-Whitney test for difference between women and men

The reference range at 2.5–97.5 percentile interval is 0.18–2.61 μM for females and 0.17–1.88 μM for males.

Univariate statistical analysis did not show significant correlation between LPA and age (Spearman’s R = 0.16, p = 0.12 in total group; R = 0.18 p = 0.20 in women and R = 0.22; p = 0.23 in men), but suggested that positive association may exist in both sex groups (Fig. 1). Multivariate analysis taking into account age and sex showed that both older age and female sex are significant independent predictors of higher LPA concentrations (Table 4). On the basis of GLM equation coefficients the following formula for calculation of LPA concentration adjusted for age and sex (LPAadj) was derived:
$$ {LPA}_{adj}\ \left[\mu M\right]={\mathrm{e}}^{\ln\ \left(LPA\ \left[\mu M\right]\right)-0.0108\ast \mathrm{age}\ \left[\mathrm{years}\right]+0.3068\ \left(\mathrm{if}\ \mathrm{male}\ \mathrm{sex}\right)} $$
Fig. 1

Correlation of LPA with age in women and men subgroups. LPA concentrations are presented with logarithmic scale

Table 4

Multivariate analysis (GLM) of influence of age and sex on logarithm of LPA concentrations in the study group (n = 100)

Independent variables

Coefficient in GLM equation ± standard error

P

Intercepta

−0.6098 ± 0.1957

0.002

Male sex

−0.3068 ± 0.1338

0.024

Age [years]

0.0108 ± 0.0046

0.022

R2 = 0.087, p = 0.012 for the whole GLM

aIntercept value approximates the mean logarithm of LPA concentrations adjusted for females at age 0 and corresponds to 0.543 μM

The median (interquartile range) for the LPAadj in our group of volunteers is 0.56 (0.38–0.80) μM and the reference range at 2.5–97.5 percentile interval is 0.14–1.64 μM.

LPA showed statistically significant positive correlations with BMI in the whole group (R = 0.22; p = 0.034) and in men subgroup (R = 0.31; p = 0.041) (Fig. 2) and with body mass in women subgroup (R = 0.29; p = 0.041) (Fig. 3). Overweight and obese patients had significantly higher plasma LPA concentrations than patients with BMI <25 kg/m2 (p = 0.024 and p = 0.047, respectively, Fig. 4).
Fig. 2

Correlation of LPA with BMI in women and men subgroups. LPA concentrations are presented with logarithmic scale

Fig. 3

Correlation of LPA with body mass in women and men subgroups. LPA concentrations are presented with logarithmic scale

Fig. 4

Association between LPA and BMI range. Underweight/normal – BMI <25; Overweight – BMI 25–29.99; Obese – BMI ≥30 kg/m2. LPA concentrations [μmol/L] are presented with logarithmic scale. * Wilcoxon signed-rank test

Among the lipid parameters LPA was positively correlated with TC (R = 0.32; p = 0.0011, Fig. 5) and TAG (R = 0.21; p = 0.0032, Fig. 6) in total group, TAG (R = 0.29; p = 0.036) in women and TC (R = 0.33; p = 0.026) in men subgroup. In the total group and men subgroup negative correlation between LPA and albumin was observed (R = −0.24; p = 0.016 and R = −0.30; p = 0.041, respectively). In men subgroup LPA was positively correlated with UA (R = 0.37; p = 0.011). In women subgroup LPA was negatively correlated with eGFR (R = −0.30; p = 0.029). No correlations were observed between LPA and total protein, glucose, creatinine and cholesterol of HDL or LDL fraction. Similar correlations with eGFR in women subgroup and with BMI, TC, UA and albumin in men subgroup were observed for LPAadj (Table 5). However, only positive correlation with TC remained significant for LPAadj in the whole study group. There were no statistically significant differences in LPA plasma concentrations between smokers (N = 21) and non-smokers (N = 71) (p = 0.91).
Fig. 5

Correlation between LPA and total cholesterol. LPA concentrations are presented with logarithmic scale

Fig. 6

Correlation between LPA and triacylglycerols (TAG). LPA concentrations are presented with logarithmic scale

Table 5

Correlations between LPA and other parameters in the study group. Spearman rank correlations coefficients are presented for raw (LPA) and sex- and age-adjusted (LPAadj) concentrations

 

Total

Women

Men

N

LPA

LPAadj

N

LPA

LPAadj

N

LPA

LPAadj

Age

100

0.156

−0.029

53

0.181

−0.071

47

0.224

−0.008

Body mass

96

0.032

0.136

51

0.287*

0.170

45

0.161

0.228

BMI

96

0.216*

0.185

51

0.240

0.078

45

0.306*

0.302*

Creatinine

100

−0.118

0.081

53

−0.001

0.190

47

−0.186

−0.047

eGFR

100

−0.170

−0.109

53

−0.302*

−0.308*

47

0.075

0.129

TC

100

0.320*

0.289*

53

0.261

0.219

47

0.326*

0.358*

LDL-C

100

0.190

0.177

53

0.210

0.214

47

0.092

0.140

HDL-C

100

0.105

0.034

53

−0.062

−0.180

47

0.284

0.214

TAG

100

0.214*

0.171

53

0.289*

0.202

47

0.022

0.071

Glucose

100

0.074

0.050

53

0.201

0.188

47

−0.101

−0.076

UA

100

0.019

0.058

53

−0.051

−0.197

47

0.367*

0.352*

TP

100

0.142

0.142

53

0.159

0.233

47

0.002

0.012

Albumin

100

−0.241*

−0.165

53

−0.082

−0.023

47

−0.299*

−0.291*

*p < 0.05

In circadian rhythm analysis, LPA differed slightly depending on the time of the day, but this relationship did not reach statistical significance (Fig. 7). At 2 a.m. LPA concentrations were significantly lower than at 2 p.m. (p = 0.04). No significant differences between the samples taken at 7 a.m. and at any other time of the day were found.
Fig. 7

Circadian rhythm of plasma LPA concentrations in a subgroup of 40 subjects. LPA concentrations are presented with logarithmic scale. Friedman’s ANOVA p = 0.09. * Wilcoxon signed-rank test

Discussion

LPA is promising candidate for diagnostic marker, but before its application in routine diagnostics many issues need to be taken into account. One of them is selection of proper material and method. In order to ensure conditions as close as possible to those used for other plasma parameters and most of the previous scientific studies on LPA, in the current study blood was drown from the peripheral vein to standard EDTA containing tubes and plasma samples were obtained by centrifugation of the samples at room temperature. In serum samples concentration of LPA grows much faster than in plasma during incubation, therefore serum samples are not recommended for LPA quantification [26]. According to Nakamura et al. [27] optimal material for LPA quantification is plasma obtained by centrifugation of whole blood samples collected to the tubes containing 7.5% EDTA with 10% CTAD (citrate, theophylline, adenosine, and dipyridamole) as an anticoagulant. This procedure inhibits in vitro LPA production to the greatest extent. However in cited study [27] using standard EDTA containing tubes did not cause significant increase in LPA concentrations after one hour incubation at room temperature and these blood collection tubes are commercially available.

The next step was the selection of optimal method. There are many methods for LPA quantification (for review see [28]). Some of them allow quantification of LPA molecular species and other only total LPA concentration in the samples. All of these methods differ in process of sample preparation, sensitivity, required equipment and time and labor consumption. The most widely studied method in scientific research is liquid chromatography with a double mass spectrometry (LC/MS/MS). The main disadvantage of this method is the necessity of possessing expensive equipment not available in most laboratories. Therefore we chose enzyme-linked immunosorbent assay (ELISA) as a method of LPA quantification, because of its relatively small equipment requirements and no need of prior lipid extraction which makes it possible to be used in routine diagnostics.

Mean LPA concentration obtained in the current study for healthy subjects was 0.89 ± 0.60 μM. This result was slightly higher than those obtained previously in healthy subjects with the use of methods based on liquid or gas chromatography, much higher than those obtained with the enzymatic assay and lower than in other assays (see Table 6). It should be noted, however, that these results are dependent not only on the measurement method and sample preparation procedures but also on the criteria of selection for the healthy subjects in the cited studies.
Table 6

Comparison of mean LPA concentrations obtained in healthy subjects in previous studies. W- women, M- men, GC – gas chromatography, LC – liquid chromatography, MS- mass spectrometry

Source

Method

Size of the group (N)

LPA (μM)

Mean ± SD

Bese et al. [17]

GC/MS

50 (W)

0.6 ± 0.42

Scherer et al. [35]

LC/MS/MS

10

0.699 ± 0.2

Baker et al. [36]

LC/MS

10

M: 0.61 ± 0.14

W: 0.74 ± 0.17

Xu et al. [37]

GC

48 (W)

0.6 ± 0.19

Hosogaya et al. [29]

Enzymatic

146

M: 0.077 ± 0.026

W: 0.103 ± 0.032

Li et al. [38]

LC/ measurement of inorganic phosphorus

136

1.77 ± 1.04

Yao et al. [30]

Microcolumn/ measurement of inorganic phosphorus

670

2.57 ± 1.96

Sedláková et al. [39]

Capillary electrophoresis

27

3.1 (range 0.94–9.73)

In the current study significantly higher concentrations of LPA were observed in women than in men. These results are consistent with Hosogaya et al. study [29], but opposite to Yao study [30] in which no significant differences were observed. Higher LPA concentrations in women may results from higher lysophospholipase D activity in women than in men [31].

The influence of the age on LPA concentrations is controversial. Yao et al. [30] did not observe influence of the age on LPA concentrations. Hosogaya et al. [29] observed negative correlation between age and LPA in women and no correlation in total group. In the current study correlation between age and LPA did not achieve statistical significance in univariate analysis, but multivariate analysis showed that both older age and female sex are independent significant predictors of higher plasma LPA. Future studies are necessary to confirm and explain this relationship.

The study showed that overweight and obesity are associated with significantly higher plasma LPA. This relationship may results from the role of LPA in pathophysiology of obesity. ATX – LPA signaling axis is probably engaged in inhibition of adipose tissue expansion [32]. In human, obesity is associated with higher ATX expression in visceral adipose tissue [33]. Study of Dusaulcy et al. [34] on transgenic mice carrying a null ATX allele specifically in adipose tissue (FATX-KO) showed enhanced nutritional fattening and about 40% reduced plasma LPA compared to wild-type mice. This observation indicates the potential influence of adipose tissue on the plasma LPA concentration and may explain association of higher plasma LPA with overweight/obesity.

Obesity is often associated with dyslipidemia. Plasma LPA concentration was positively correlated with serum TC and TAG and the correlation with TC remained significant for sex- and age-adjusted LPAadj. This result is consistent with the Yao et al. study [30] showing that patients with hyperlipidemia (defined as TC ≥ 5.18 mmol/l or LDL-C ≥ 3.37 mmol/l) have higher LPA plasma concentrations than control group. Negative correlation of LPA with eGFR and positive correlation between LPA and UA may suggest its potential association with renal function. Mechanisms of above relationships are not known and remain to be clarified in future studies.

It seems that there is no specific circadian rhythm of LPA concentrations. The only observed significant difference was lower concentration at 2 a.m. at night than in the afternoon. There were no significant differences between samples in the morning at 7 a.m. in fasting state and samples taken at any of the other three time points. Therefore time of donation and prior fasting seem to have negligible influence on the measurement.

Conclusions

In conclusion the reference range for the plasma LPA concentration corrected for age and sex (LPAadj), determined at 2.5–97.5 percentile interval is 0.14–1.64 μM. There are many factors associated with LPA plasma concentrations in healthy subjects. Women have higher plasma LPA concentrations than men; therefore sex should be taken into account in the establishing of reference LPA values. Age seems to be positively associated with LPA concentrations. Another important notice is association between LPA and BMI and/or body mass. Obese people may have higher plasma LPA concentrations and this factor should be considered during interpretation of assay results. Smoking probably does not influence LPA concentrations. Plasma LPA is positively correlated with serum TC, TAG and UA, while correlation with albumin and eGFR is negative. It seems that LPA concentrations have no specific circadian rhythm, therefore the time of blood donation and fasting state have marginal effect on LPA concentrations. We believe that these findings will be helpful in future application of LPA as a diagnostic marker.

Abbreviations

ATX: 

Autotoxin

BMI: 

Body mass index

eGFR: 

estimated glomerular filtration rate

GLM: 

General linear model

HDL-C: 

Cholesterol of high density lipoproteins

LDL-C: 

Cholesterol of low density lipoproteins

LPA: 

Lysophosphatidic acid

LPA1–6: 

Lysophosphatidic acid receptors 1–6

LPC: 

Lysophosphatidylcholine

TAG: 

Triacylglycerols

TC: 

Total cholesterol

TP: 

Total protein

Declarations

Acknowledgments

Not applicable.

Funding

The study was supported by the Pomeranian Medical University project for young scientists “Młody Badacz” (MB-130-140/15).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

AM participated in the planning of the study, experiment work, data analysis, and manuscript preparation. KS supervised and participated in the planning of the study, data analysis, and manuscript preparation. MB participated in planning of the study and experiment work. BD and DC supervised the planning of the study and manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study had approval from the Local Bioethics Committee at the Pomeranian Medical University in Szczecin (the study numbers KB-0012/36/11, KB-0012/84/12, KB-0012/130/15 and KB-0012/162/12) and written informed consent was obtained from all volunteers.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin
(2)
Department of Medical Analytics, Pomeranian Medical University in Szczecin
(3)
Department of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University in Szczecin

References

  1. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55(7):1192–214.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3(8):582–91.View ArticlePubMedGoogle Scholar
  3. Li YF, Li RS, Samuel SB, Cueto R, Li XY, Wang H, et al. Lysophospholipids and their G protein-coupled receptors in atherosclerosis. Front Biosci (Landmark Ed). 2016;21(1):70–88.View ArticlePubMed CentralGoogle Scholar
  4. Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling in the nervous system. Neuron. 2015;85(4):669–82.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Sheng X, Yung YC, Chen A, Chun J. Lysophosphatidic acid signalling in development. Development. 2015;142(8):1390–5.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Teo ST, Yung YC, Herr DR, Chun J. Lysophosphatidic acid in vascular development and disease. IUBMB Life. 2009;61(8):791–9.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol. 2010;161(2):241–70.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Blackburn J, Mansell JP. The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone. 2012;50(3):756–62.View ArticlePubMedGoogle Scholar
  9. Aikawa S, Hashimoto T, Kano K, Aoki J. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157(2):81–9.View ArticlePubMedGoogle Scholar
  10. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen. 2007;15(5):607–16.View ArticlePubMedGoogle Scholar
  11. Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal Transduct Res. 2015;35(6):578–84.View ArticlePubMedGoogle Scholar
  12. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010;91(3–4):130–8.View ArticlePubMedGoogle Scholar
  13. Pradere JP, Gonzalez J, Klein J, Valet P, Gres S, Salant D, et al. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta. 2008;1781(9):582–7.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Budd DC, Qian Y. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis. Future Med Chem. 2013;5(16):1935–52.View ArticlePubMedGoogle Scholar
  15. Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55(6):1010–8.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Meleh M, Pozlep B, Mlakar A, Meden-Vrtovec H, Zupancic-Kralj L. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858(1–2):287–91.View ArticlePubMedGoogle Scholar
  17. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, et al. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol. 2010;21(4):248–54.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res. 2002;43(12):2049–55.View ArticlePubMedGoogle Scholar
  19. Ohkawa R, Hisano N, Nakamura K, Okubo S, Yokota H, Yatomi Y. Lysophospholipase D activity exists in the urine to catalyse the formation of lysophosphatidic acid. Nephrol Dial Transplant. 2006;12:3612–3.View ArticleGoogle Scholar
  20. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002;1582(1–3):204–15.View ArticlePubMedGoogle Scholar
  21. Lu Z, Chen Y, Hu Z, Hu C. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2015;25(1):18–23.View ArticlePubMedGoogle Scholar
  22. Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Kishimoto T, Miyazaki T, et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin Chim Acta. 2012;413(1–2):207–12.View ArticlePubMedGoogle Scholar
  23. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41(6):616–23.View ArticlePubMedGoogle Scholar
  24. Sasagawa T, Suzuki K, Shiota T, Kondo T, Okita M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J Nutr Sci Vitaminol (Tokyo). 1998;44(6):809–18.View ArticleGoogle Scholar
  25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277(50):48737–44.View ArticlePubMedGoogle Scholar
  27. Nakamura K, Kishimoto T, Ohkawa R, Okubo S, Tozuka M, Yokota H, et al. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem. 2007;367(1):20–7.View ArticlePubMedGoogle Scholar
  28. Jesionowska A, Cecerska E, Dolegowska B. Methods for quantifying lysophosphatidic acid in body fluids: a review. Anal Biochem. 2014;453:38–43.View ArticlePubMedGoogle Scholar
  29. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H, et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem. 2008;45(Pt 4):364–8.View ArticlePubMedGoogle Scholar
  30. Yao CS, Yan SG, Gao LS, Sun ZR, Liu F, Jiang B, et al. Patients with risk factors have higher plasma levels of lysophosphatidic acid: a promising surrogate marker for blood platelet activation. Blood Coagul Fibrinolysis. 2014;25(4):322–5.View ArticlePubMedGoogle Scholar
  31. Nakamura K, Ohkawa R, Okubo S, Tozuka M, Okada M, Aoki S, et al. Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem. 2007;40(3–4):274–7.View ArticlePubMedGoogle Scholar
  32. Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 2014;96:140–3.View ArticlePubMedGoogle Scholar
  33. Rancoule C, Dusaulcy R, Treguer K, Gres S, Guigne C, Quilliot D, et al. Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem. 2012;68(4):635–44.View ArticlePubMedGoogle Scholar
  34. Dusaulcy R, Rancoule C, Gres S, Wanecq E, Colom A, Guigne C, et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res. 2011;52(6):1247–55.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Scherer M, Schmitz G, Liebisch G. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin Chem. 2009;55(6):1218–22.View ArticlePubMedGoogle Scholar
  36. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem. 2001;292(2):287–95.View ArticlePubMedGoogle Scholar
  37. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280(8):719–23.View ArticlePubMedGoogle Scholar
  38. Li ZG, Yu ZC, Wang DZ, Ju WP, Zhan X, Wu QZ, et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol Res. 2008;30(4):366–9.View ArticlePubMedGoogle Scholar
  39. Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 2011;32(2):311–6.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement